MassBioDrive header

Fall 2022 Cohort

AdductNE, LLC

Based in Omaha, NE

AdductNE is a radiopharmaceutical company spun-out from the University of Nebraska Medical Center (UNMC) in 2019. AdductNE is dedicated to developing targeted imaging and therapeutic agents for cancer.

Jered Christopher Garrison, Ph.D.,
President and
Chief Scientific Officer
Shana Garrison, Ph.D.,
Chief Financial Officer

Based in Mississauga, Ontario, CA

HDAX Therapeutics is developing a targeted therapeutics platform for the safe and efficacious treatment of HDAC-driven pathologies such as neuropathies and cancers by rationally designing therapies to overcome common drug challenges including weak binding, off-target toxicities, and poor pharmacokinetic profiles.

Nabanita Nawar, Ph.D.,
Chief Executive Officer 
Pimyupa Manaswiyoungkul, Ph.D.,
Chief Operations Officer
Olasunkanmi Olaoye, Ph.D.,
Vice President Drug Discovery 
Elvin de Araujo, Ph.D.,
Chief Innovation Officer
Patrick Gunning, Ph.D., Scientific Advisor 

Hybridex Biosciences

Based in New Haven, CT

Hybridex Biosciences is an early-stage biotech company aiming to enable the next-generation of safe gene editing. Using its tunable antisense nucleic acid platform, developed in labs at Yale University, Hybridex aims to improve the safety and control of CRISPR-based systems to realize the full potential of gene editing therapeutics.

Jem Atillasoy, MD Candidate
Co-Founder
Nicholas Economos, MD/Ph.D. Candidate,
Co-Founder

Based in Montreal, Quebec CA

Jenthera Therapeutics is a preclinical biotechnology company leveraging a novel non-viral, non-lipid CRISPR platform for the development of groundbreaking therapeutics. The platform presents tissue-specific delivery, built-in safety, and advanced gene correction capabilities, proposing to unlock new realms of therapeutic possibilities and allow for the development of complex multi-loci corrective gene therapies.

Dr. Philip Roche
Chief Executive Officer, Chief Scientific Officer 
Laurent D. Ziri, CPA-CA, Chief Operations Officer 
Sandra Azoulay, CPA-CA, Chief Financial Officer, Communications 

Based in Knoxville, TN

Orion Therapeutics has developed a patented lipid-based nanoparticle capable of safe, effective, and targeted delivery of RNA medicine to diseased tissues to address the delivery barrier to successful gene therapy. This technology will be licensed to pharmaceutical partners to facilitate success of RNA therapeutics and vaccine programs.

Trey Fisher, Ph.D.,
Co-Founder and
Chief Executive Officer 
Michael McCaman, Ph.D., Co-Founder, President, Director of Strategic Planning 
Deidra Mountain
Co-Founder, Director of Vascular Therapeutics Pipeline 
Jennifer Zachry
Co-Founder, Director of Business Development 

Based in Natick, MA

PacDNA is an oligonucleotide therapeutics company that will expand the horizon of this drug modality to include previously inaccessible organs and tissues. Its proprietary oligonucleotide enhancer technology will be a new drug production engine, producing more potent clinical leads with fewer side effects at a lower cost. 

Chad A. Mirkin, Ph.D.,
Professor  
Ke Zhang, Ph.D.,
Chief Executive Officer and Professor 

Spring 2022 Cohort

Artificial Axon Labs Inc.

Based in Massachusetts

Anna Jagielska, Ph.D., President, CEO, CSO, & Co-Founder
Kavin Kowsari, Vice-President, CTO, & Co-Founder

Artificial Axon Labs is developing a transformational drug discovery platform to discover medicines for neurodegenerative diseases. Our technology, developed by the

company founders at MIT, combines novel biocompatible materials, state-of-the-art 3D printing of axon mimics (Artificial Axons), and patient-derived human cells to generate first-in-class remyelinating drugs for Multiple Sclerosis.


Atorvia Health Technologies

Based in Canada

Jane Lapon, CEO
David Allinson, CFO & Head of Business Development
Nermeen Varawalla MD, Chair Clinical Advisory Group
Steven C. Borkan MD, Associate Professor, Boston Medical Centre

Atorvia’s purpose is to transform outcomes for patients with severe medical conditions.  Our initial focus is acute kidney injury (AKI), a devastating condition which affects millions worldwide yet still lacks effective therapy.  To address this crisis, we are developing a kidney-targeted peptide that prevents regulated cell death and kidney failure.


Modulari-T Biosciences

Based in Canada

David Cotnoir-White, Ph.D., CEO & Co-Founder
Étienne Gagnon, Ph.D., CSO & Co-Founder

Modulari-T is a preclinical stage immunotherapy startup developing a novel platform, the MARC, to reprogram immune cells for oncology and beyond. Our MARC technology is twice as potent as CAR-T while reducing side-effects ten-fold which will enable adoptive cell therapy to break-in to new indications in autoimmunity and regenerative medicine.


PhenoTarget Biosciences, Inc.

Based in California

Shoutian Zhu, Ph.D., CEO
Wenshe Liu, Ph.D., CSO
James Schaeffer, Ph.D., CBO

PhenoTarget Biosciences, Inc. is a biotech startup focused on the discovery and development of first-in-class therapies for unmet medical needs including oncology, fibrosis, cardiovascular diseases and infectious diseases. We are modality agnostic that our pipeline and technology platforms span small molecules to functionalized peptides and next generation cell therapies.


SYTE.bio, Inc.

Based in Massachusetts

Martin Williams, CEO & Founder

SYTE.bio is an early-stage synthetic biology company focused on the discovery, development and future commercialization of precision therapeutics using its proprietary Linear DNA and Circular RNA technology platforms. SYTE.bio aims to deliver novel and effective therapeutics and vaccines enabling precise corrective and preventive treatments for patients worldwide.